GALECTIN THERAPEUTICS INC. Preferred Stock, Par or Stated Value Per Share
GALECTIN THERAPEUTICS INC. (GALT) had Preferred Stock, Par or Stated Value Per Share of $0.01 per share as of 2010-12-29, per its 10-K filed 2021-03-31.
Discontinued › Balance Sheet › Equity › Preferred Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:PreferredStockParOrStatedValuePerShare · last filed 2021-03-31
- 2010-12-29: Preferred Stock, Par or Stated Value Per Share $0.01.
| Period end | Preferred Stock, Par or Stated Value Per Share |
|---|---|
| 2010-12-29 | $0.01 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |